ESR1 and neoplasm: The presence of ESR1 mutations is associated with other genetic and epigenetic alterations; therefore, testing of novel therapeutic agents and their combinations in preclinical models that include different genetic backgrounds is crucial and highlights the potential of patient-derived xenografts and ex vivo cultures of circulating tumor cells (CTCs) from patients with metastatic ER+ breast cancer.